id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-N-0279-0011,FDA,FDA-2011-N-0279,"Agency Information Collection 
Activities; Proposed Collection; 
Comment Request; Prescription Drug 
Marketing; Administrative Procedures, 
Policies, and Requirements",Notice,Request for Comments,2021-03-12T05:00:00Z,2021,3,2021-03-12T05:00:00Z,2021-05-12T03:59:59Z,2023-07-06T16:05:10Z,2021-05214,0,0,0900006484a68d5f
FDA-2011-N-0279-0012,FDA,FDA-2011-N-0279,"Agency Information Collection Activities; Proposed Collection; Comment Request; Prescription Drug Marketing; Administrative Procedures, Policies, and Requirements",Notice,60 Day Proposed Information Collection,2021-03-12T05:00:00Z,2021,3,2021-03-19T04:00:00Z,2021-05-12T03:59:59Z,2021-03-22T18:43:21Z,2021-05214,0,0,0900006484a71c11